Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The main objective of this research is to develop and evaluate new PET imaging agents with high sensitivity and specificity for prostate cancer and other aggressive tumors. Specifically, the research focuses on improving upon existing prostate cancer imaging methods, such as PSA tests and PSMA PET/CT, which have limitations in sensitivity, specificity, and the ability to provide comprehensive tumor information，and aims to create a novel PET probe targeting Trop2, an antigen highly expressed in multiple cancer types, to enable in vivo, whole-tumor assessment. This would support early diagnosis, more precise staging, and effective monitoring of cancer therapy.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients with initial diagnosis of prostate cancer, or patients with biochemical recurrence after radical prostatectomy or radical radiotherapy. 2. Estimated survival time \>3 months, as determined by a physician. 3. Willing to sign the willing to sign a consent form form voluntarily and able to comply with the study protocol. Who Should NOT Join This Trial: 1. Individuals unable to tolerate intravenous administration (e.g., history of needle or blood phobia). 2. Patients deemed unsuitable by researchers or unable to complete PET or other imaging examinations due to specific conditions, such as claustrophobia or radiophobia. 3. Individuals with occupational exposure to radiation. 4. Patients with severe diseases affecting the heart, kidneys, lungs, vascular, neurological, or mental systems, immune deficiency disorders, or hepatitis/cirrhosis. 5. Other conditions that researchers deem unsuitable for participation in the study. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Patients with initial diagnosis of prostate cancer, or patients with biochemical recurrence after radical prostatectomy or radical radiotherapy. 2. Estimated survival time \>3 months, as determined by a physician. 3. Willing to sign the informed consent form voluntarily and able to comply with the study protocol. Exclusion Criteria: 1. Individuals unable to tolerate intravenous administration (e.g., history of needle or blood phobia). 2. Patients deemed unsuitable by researchers or unable to complete PET or other imaging examinations due to specific conditions, such as claustrophobia or radiophobia. 3. Individuals with occupational exposure to radiation. 4. Patients with severe diseases affecting the heart, kidneys, lungs, vascular, neurological, or mental systems, immune deficiency disorders, or hepatitis/cirrhosis. 5. Other conditions that researchers deem unsuitable for participation in the study.

Treatments Being Tested

DIAGNOSTIC_TEST

standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11

Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.

Locations (1)

The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China